EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study

Anne-Laure Faucon iD, Stefania Lando, Charikleia Chrysostomou, Julia Wijkström iD, Sigrid Lundberg, Rino Bellocco, Mårten Segelmark, Marie Evans, Juan-Jesús Carrero iD

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.20024 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Anne-Laure Faucon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hospitalization, Glomerulosclerosis, Focal Segmental. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Swedish Research Council, Region Stockholm (Center of Innovative MEDicine (CIMED), and ALF Medicine).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although glomerular diseases are the third most frequent cause of end‐stage kidney disease worldwide, little is known about their long‐term outcomes.

Methods

In patients with chronic kidney disease (CKD) stage 3–5 enrolled in the Swedish Renal Registry, we compared risks of hospitalization, kidney replacement therapy (KRT), major cardiovascular events (MACE), and death of the four most frequent primary glomerular diseases (IgA nephropathy [IgAN], focal segmental glomerulosclerosis [FSGS], minimal change disease [MCD], and membranous nephropathy [MN]), and patients with CKD due to the most common non‐communicable diseases (control‐CKD).

Results

We identified 2396 patients with glomerular disease (97% biopsy‐proven, 69% men, 57 years, eGFR 29 mL/min/1.73 m 2 , uACR 88 mg/mmol, 1524 with IgAN, 398 FSGS, 94 MCD, and 380 MN) and 37,697 controls (64% men, 74 years, eGFR 25 mL/min/1.73 m 2 , uACR 23 mg/mmol), mainly with diabetic nephropathy and nephroangiosclerosis. The median follow‐up was 6.3 (3.3; 9.9) years. Compared with control‐CKD, patients with primary glomerular diseases generally had a lower risk of hospitalization, MACE (adjusted hazard ratios [HRs] ranging from 0.44 to 0.88 depending on the etiology) and death (HRs ranging 0.45–0.76). Patients with IgAN and FSGS had a faster eGFR decline and a higher rate of KRT (HRs 1.26 [95%CI: 1.15–1.37] and 1.34 [1.15–1.57], respectively). Conversely, patients with MN and MCD had a lower KRT rate and slower eGFR decline.

Conclusion

Despite having a lower relative risk of hospitalization, cardiovascular events and mortality, patients with IgAN and FSGS are at higher risk of CKD progression than the most common etiologies of CKD, emphasizing the need for more stringent treatment strategies in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationGlomerulosclerosis, Focal SegmentalHumansMaleFemaleMiddle AgedSwedenAgedRenal Insufficiency, ChronicCardiovascular DiseasesRenal Replacement TherapyGlomerulonephritis, MembranousNephrosis, LipoidCohort StudiesRegistriesGlomerulonephritis, IGAGlomerular Filtration RateAdult

Stichwörter der Autor:innen

IgA nephropathychronic kidney diseasefocal segmental glomerulosclerosisoutcomesprimary glomerular disease

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Epidemiology, INSERM UMR 1018, Centre for Epidemiology and Population Health, Paris-Saclay University, Paris, France.
  • Department of Biostatistics, University of Milano-Bicocca, Milan, Italy.
  • Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medical Specialist Care, Nephrology Clinic, Danderyd University Hospital, Stockholm, Sweden.

ORCID-Profile: Anne-Laure Faucon, Julia Wijkström, Juan-Jesús Carrero

Förderung

  • NIDDK NIH HHS
  • Swedish Research Council
  • Region Stockholm (Center of Innovative MEDicine (CIMED), and ALF Medicine)
  • CSL Vifor
  • Swedish Heart and Lung Foundation
  • US National Institute of Health
  • Vetenskapsrådet

Zitieren

APA

Faucon, A. L., Lando, S., Chrysostomou, C., Wijkström, J., Lundberg, S., Bellocco, R., Segelmark, M., Evans, M., & Carrero, J. J. (2025). Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study. Journal of Internal Medicine. https://doi.org/10.1111/joim.20024

Vancouver

Faucon AL, Lando S, Chrysostomou C, Wijkström J, Lundberg S, Bellocco R, et al. Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study. Journal of Internal Medicine. 2025. doi:10.1111/joim.20024

BibTeX
@article{Faucon2025,
  author = {Faucon, Anne-Laure and Lando, Stefania and Chrysostomou, Charikleia and Wijkström, Julia and Lundberg, Sigrid and Bellocco, Rino and Segelmark, Mårten and Evans, Marie and Carrero, Juan-Jesús},
  title = {Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.20024}
}
Kostenlos starten →